Keyphrases
Plasmodium Falciparum
100%
Indonesia
99%
Primaquine
50%
Plasmodium Vivax
50%
West Timor
48%
Mass Treatment
46%
Mass Screening
46%
Malaria
46%
Dihydroartemisinin-piperaquine
36%
Gametocyte
30%
Glucose-6-phosphate Dehydrogenase (G6PD)
29%
Falciparum Malaria
28%
Malaria Transmission
25%
Longitudinal Prospective Study
23%
Pfs25
23%
Pvs25
23%
Merozoite Antigens
23%
Seasonal Changes
23%
Gametocyte Development
23%
Malaria Endemicity
23%
Lampung
23%
Eastern Indonesia
23%
Malaria Control
23%
Co-epidemics
23%
Piperaquine
23%
Malaria Endemic Areas
23%
Randomized Controlled Trial
23%
Malaria Elimination
23%
Antibody Response
23%
Gametocyte Carriage
23%
Cluster Randomized Trial
23%
Transmission Dynamics
23%
South Sumatra
23%
Rubber Band
15%
Low Transmission
14%
Piperaquine Resistance
13%
Antibody Level
11%
High Transmission
11%
Transmission Season
11%
Purworejo
11%
MST3
10%
MST2
10%
Confidence Interval
9%
Screening Interventions
9%
Treatment Interventions
9%
Clinical Trial Registry
8%
Seroconversion Rate
7%
PfAMA1
7%
Passive Ranging
7%
Seroprevalence
7%
Immunology and Microbiology
Primaquine
50%
Plasmodium vivax
50%
Plasmodium falciparum
49%
Mass Screening
46%
Gametocyte
46%
Piperaquine
26%
Merozoite
23%
Membrane Antigen
23%
Antibody Response
23%
Dynamics
23%
Malaria Control
23%
Gene Linkage Disequilibrium
11%
Population Structure
11%
Prevalence
9%
Hemoglobin Blood Level
9%
Polymerase Chain Reaction
8%
Seroconversion
7%
Seroprevalence
7%
Screening
6%
Population Differentiation
5%
Zoonosis
5%
Arm
5%
Pharmacology, Toxicology and Pharmaceutical Science
Primaquine
54%
Piperaquine
54%
Dihydroartemisinin
38%
Glucose 6 Phosphate Dehydrogenase
34%
Plasmodium falciparum
26%
Infection
26%
Malaria Falciparum
23%
Randomized Controlled Trial
23%
Cluster Randomized Trial
23%
Malaria
23%
Plasmodium Vivax Malaria
11%
Clinical Trial
10%
Artemisinin
9%
Normal Human
7%
Disease
7%
Antimalarial Agent
7%
Combination Therapy
5%